About Pulmorphix

About company

Pulmorphix has developed the world’s first lung biosimulator device to allow investigation of dissolution behaviour of orally inhaled products (OIPs). The biosimulator mimics lung conditions allowing analysts in the pharmaceutical industry to examine the initial interaction of their formulations with the lung lining fluids under “real life” scenarios. To date, the challenge with OIPs has been to deliver them to all parts of the lung. There have been significant developments in terms of inhalation devices and formulations to physically channel the drug into the deep lung.